JP7583741B2 - リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法 - Google Patents

リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法 Download PDF

Info

Publication number
JP7583741B2
JP7583741B2 JP2021560323A JP2021560323A JP7583741B2 JP 7583741 B2 JP7583741 B2 JP 7583741B2 JP 2021560323 A JP2021560323 A JP 2021560323A JP 2021560323 A JP2021560323 A JP 2021560323A JP 7583741 B2 JP7583741 B2 JP 7583741B2
Authority
JP
Japan
Prior art keywords
composition
mole percent
liposome
percent
glycero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527638A (ja
JP2022527638A5 (enExample
Inventor
アグネス ラファルコ，
鉄平 白倉
サミュエル エリック グリーンバーグ，
Original Assignee
グライコミン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グライコミン， インコーポレイテッド filed Critical グライコミン， インコーポレイテッド
Publication of JP2022527638A publication Critical patent/JP2022527638A/ja
Publication of JP2022527638A5 publication Critical patent/JP2022527638A5/ja
Application granted granted Critical
Publication of JP7583741B2 publication Critical patent/JP7583741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021560323A 2019-03-29 2020-03-27 リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法 Active JP7583741B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
US62/826,874 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (3)

Publication Number Publication Date
JP2022527638A JP2022527638A (ja) 2022-06-02
JP2022527638A5 JP2022527638A5 (enExample) 2023-04-03
JP7583741B2 true JP7583741B2 (ja) 2024-11-14

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560323A Active JP7583741B2 (ja) 2019-03-29 2020-03-27 リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法

Country Status (19)

Country Link
US (1) US20220184107A1 (enExample)
EP (1) EP3946365A4 (enExample)
JP (1) JP7583741B2 (enExample)
KR (1) KR20210143906A (enExample)
CN (1) CN113873998A (enExample)
AR (1) AR119705A1 (enExample)
AU (1) AU2020252005B2 (enExample)
BR (1) BR112021019593A2 (enExample)
CA (1) CA3134828A1 (enExample)
CL (1) CL2021002512A1 (enExample)
CO (1) CO2021014274A2 (enExample)
EA (1) EA202192663A1 (enExample)
IL (1) IL286713B2 (enExample)
MX (1) MX2021011876A (enExample)
PE (1) PE20212366A1 (enExample)
PH (1) PH12021552428A1 (enExample)
SG (1) SG11202110623PA (enExample)
TW (1) TWI906214B (enExample)
WO (1) WO2020205530A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205628A1 (en) * 2022-04-18 2023-10-26 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525461A (ja) 2011-08-31 2014-09-29 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
JP2016509572A (ja) 2012-11-05 2016-03-31 プロナイ セラピューティクス インコーポレイテッド Ｂｃｌ２発現の調節による癌の処置のためにバイオマーカーを使用する方法
US20160228364A1 (en) 2013-09-16 2016-08-11 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use
JP2017537650A (ja) 2014-10-09 2017-12-21 ライポテック・ピーティーワイ・リミテッド キメラタンパク質

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156783B1 (en) * 1999-03-02 2007-10-24 Transave, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
WO2002076428A1 (en) * 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
AU2003205048B2 (en) * 2002-01-09 2009-02-26 Transave, Inc. Efficient liposomal encapsulation
WO2003059322A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
WO2010130896A2 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
US20170165374A1 (en) * 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525461A (ja) 2011-08-31 2014-09-29 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
JP2016509572A (ja) 2012-11-05 2016-03-31 プロナイ セラピューティクス インコーポレイテッド Ｂｃｌ２発現の調節による癌の処置のためにバイオマーカーを使用する方法
US20160228364A1 (en) 2013-09-16 2016-08-11 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use
JP2017537650A (ja) 2014-10-09 2017-12-21 ライポテック・ピーティーワイ・リミテッド キメラタンパク質

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Advanced Drug Delivery Reviews，2019年02月，Vol.151-152，pp.233-244
Asian Journal of Pharmaceutical Sciences，2015年，Vol.10, No.2，pp.81-98
Colloids and Surfaces B: Biointerfaces，2015年，Vol.136，pp.514-526

Also Published As

Publication number Publication date
EP3946365A4 (en) 2023-04-19
SG11202110623PA (en) 2021-10-28
CN113873998A (zh) 2021-12-31
AU2020252005A1 (en) 2021-11-04
JP2022527638A (ja) 2022-06-02
MX2021011876A (es) 2022-01-04
AR119705A1 (es) 2022-01-05
CL2021002512A1 (es) 2023-01-06
KR20210143906A (ko) 2021-11-29
AU2020252005B2 (en) 2025-11-27
CA3134828A1 (en) 2020-10-08
EP3946365A1 (en) 2022-02-09
EA202192663A1 (ru) 2022-03-01
TWI906214B (zh) 2025-12-01
US20220184107A1 (en) 2022-06-16
WO2020205530A1 (en) 2020-10-08
IL286713A (en) 2021-10-31
IL286713B1 (en) 2025-03-01
PE20212366A1 (es) 2021-12-21
IL286713B2 (en) 2025-07-01
BR112021019593A2 (pt) 2021-12-14
TW202102231A (zh) 2021-01-16
CO2021014274A2 (es) 2022-01-17
PH12021552428A1 (en) 2022-07-11

Similar Documents

Publication Publication Date Title
EP2323693B1 (en) Drug carriers
US20240082155A1 (en) Pharmaceutical preparation of carbohydrates for therapeutic use
EP2356990A2 (en) Liposome treatment of viral infections
JP7583741B2 (ja) リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法
JP6744046B2 (ja) ｃＧＭＰアナログの標的化されたリポソーム送達
US20080279916A1 (en) Liposome Preparation
US20240277740A1 (en) Treatment of known and unknown viral infection with lipid agents
EA050120B1 (ru) Липосомальные фармацевтические композиции и способ их применения
WO2020061670A1 (pt) Formulação lipossomal, composição farmacêutica, uso de uma formulação lipossomal, método para tratamento de câncer, e, processo para preparação de uma formulação lipossomal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241101

R150 Certificate of patent or registration of utility model

Ref document number: 7583741

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150